# Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

> **NCT03520790** · PHASE1 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 36 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paricalcitol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03520790
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-05
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Phase II was not pursued due to futility based on the results of the NAPOLI-3 therapeutic clinical trial.
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520790, "Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03520790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*